CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and collaborators today presented initial results from Part C of its ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results